Anxiety in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy and Implantable Cardioverter Defibrillators

Sharlene M. Day, MD

Editorial

Diagnosis of a cardiac genetic disorder can be a life-changing event. Symptomatic status, uncertainty regarding disease progression, risk of sudden cardiac death (SCD), recommended lifestyle changes (ie, activity restrictions or career change), and genetic transmission to offspring all contribute to the potential psychological burden of disease. Most of the relevant literature on this topic focuses on 2 of the most common genetic cardiac diseases, hypertrophic cardiomyopathy and inherited long-QT syndrome. Studies on these disorders have consistently shown impairments in health status and quality of life, with an elevated risk for anxiety and depression. An implantable cardioverter defibrillator (ICD) may be indicated for primary or secondary prevention of SCD in these patients, and is likely to exacerbate psychological distress. Independent of underlying diagnosis, patients requiring ICDs commonly experience anxiety and/or depression related to the anticipation of a potential shock. Psychological implications of ICDs have been reported to be worse in patients with inherited diseases compared with ischemic or valvular heart disease. The experience of receiving 1 or more ICD shocks further negatively affects quality of life. Inappropriate shocks (ie, for sinus or supraventricular tachycardia or T-wave oversensing) can elicit similar psychological responses to appropriate shocks for life-threatening ventricular arrhythmias. This is a particularly important consideration for young patients because 1 in 4 may be expected to receive at least 1 inappropriate shock. The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.

From the Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI. Correspondence to Sharlene M. Day, MD, Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical Center, 1150 W Medical Center Dr, 7301 MSRB III, Ann Arbor, MI 48109. E-mail sday@umich.edu (Circ Cardiovasc Genet. 2012;5:2-4.) © 2012 American Heart Association, Inc. Circ Cardiovasc Genet is available at http://circgenetics.ahajournals.org DOI: 10.1161/CIRCGENETICS.111.962639

Like hypertrophic cardiomyopathy and long-QT syndrome, a diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC) carries the psychological burden of genetic transmission and risk of SCD, but patients and their health care providers face unique challenges that often begin with making the diagnosis itself. Although the modified task force criteria have improved the sensitivity without loss of specificity for diagnosis, the broad spectrum of disease, and prolonged concealed phase during which ventricular arrhythmias can occur in the absence of other definitive clinical findings, can cause a great deal of uncertainty. Further complicating the picture is the lack of systematic criteria for prophylactic ICD implantation in ARVC patients or asymptomatic gene mutation carriers. Recent data suggest high rates of appropriate ICD discharges in ARVC patients without prior ventricular tachycardia or fibrillation, with syncope being the only multivariate predictor of a life-saving ICD shock. Yet, too often, a patient’s first syncopal event results in death, making the absence of syncope an inadequate determinant of the need for ICD implantation. Unfortunately, despite the obvious value of an ICD in conferring protection against SCD in ARVC, the high rates of inappropriate shocks (19%) and device-related complications (17%) continue to be problematic. These complex issues surrounding the diagnosis and treatment algorithms for ARVC mean that extrapolation of data from the hypertrophic cardiomyopathy and long-QT syndrome literature relevant to the psychological impact of disease may underestimate its true prevalence and magnitude in this population. Only 1 recent study included ARVC patients in its assessment of health status and quality of life in those with cardiac genetic disease, and the number was small (n = 17), representing only 4% of the entire cohort.

In this issue of Circulation: Cardiovascular Genetics, James et al examine psychosocial adjustment, anxiety, and depression in 86 adult ARVC patients with ICDs. They use 4 questionnaires that assess ICD-specific anxiety (Functional Self-Appraisal Scale), device acceptance (Florida Patient Acceptance Survey), generalized anxiety and depression (Hospital Anxiety and Depression Scale), and functional capacity (Duke Activity Status Index [DASI]). They analyze associations with demographic characteristics, including sex, age, family history of ARVC, time since ICD implantation, and history of ICD shocks. The population was high risk, with more than half having received ICDs for secondary prevention, and a similar fraction having experienced at least 1 shock (most were inappropriate shocks). Despite this, the mean functional capacity was high, with a DASI score of 48.1 (ceiling value, 58.2), corresponding to an estimated peak oxygen uptake of 30.3 mL/kg per minute, which was more favorable than those of other ICD populations (mean DASI score, 17–21). This finding reflects the relative disconnect between arrhythmia risk and extent of structural and functional remodeling in ARVC.

Device acceptance scores in ARVC patients were in the range consistent with other ICD patients in previously published studies. Younger age was a significant multivariate...
Day Anxiety in ARVC Patients With ICDs

Any intervention using an exercise component in ARVC patients will need to be carefully tailored, with direct input from the cardiologist, to ensure safe exercise practices.

James et al.\(^1\) should be commended on bringing to attention the risk for poor psychosocial adjustment in patients with ARVC and ICDs. This response is one that cardiologists often overlook and urgently needs further attention and direction.

Sources of Funding

Dr Day is supported by the National Institutes of Health.

Disclosures

None.

References


Key Words: Editorials ■ implantable cardioverter defibrillator ■ arrhythmogenic right ventricular cardiomyopathy ■ psychosocial ■ genetic heart disease
Anxiety in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy and Implantable Cardioverter Defibrillators
Sharlene M. Day

Circ Cardiovasc Genet. 2012;5:2-4
doi: 10.1161/CIRCGENETICS.111.962639
Circulation: Cardiovascular Genetics is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2012 American Heart Association, Inc. All rights reserved.
Print ISSN: 1942-325X. Online ISSN: 1942-3268

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circgenetics.ahajournals.org/content/5/1/2

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Genetics can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Genetics is online at:
http://circgenetics.ahajournals.org//subscriptions/